Lakefront Biotherapeutics (LKFT) Net Cash Flow Growth (3y) (2018 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (LKFT) Net Cash Flow Growth (3y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -8.34% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 36.60% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -35.85% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 106.37% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 67.39% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.55% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 52.78% |
| 10 | Lakefront Biotherapeutics | 1.88 Bn | 1.88 Bn | 3.51 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 60.45% |
| Dec 31, 2025 | 26.33% |
| Mar 31, 2025 | 26.88% |
| Dec 31, 2024 | 26.28% |
| Jun 30, 2024 | -16.09% |
| Mar 31, 2024 | -30.51% |
| Dec 31, 2023 | 10.94% |
| Mar 31, 2023 | -34.47% |
| Dec 31, 2022 | 22.94% |
| Mar 31, 2022 | -138.05% |
| Dec 31, 2021 | -26.03% |
| Jun 30, 2021 | 57.36% |
| Mar 31, 2021 | 128.59% |
| Dec 31, 2020 | -43.13% |
| Jun 30, 2020 | -26.02% |
| Mar 31, 2020 | 277.07% |
| Dec 31, 2019 | -691.14% |
| Jun 30, 2019 | -51.50% |
| Mar 31, 2019 | -28.40% |
| Dec 31, 2018 | 1,260.74% |